PUMA SE NPV (PMMAF) Receives a Buy from Goldman Sachs
In a report released yesterday, Richard Edwards from Goldman Sachs maintained a Buy rating on PUMA SE NPV (PMMAF – Research Report), with a price target of €30.00. The company's shares closed yesterday at $25.48.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Edwards is an analyst with an average return of -5.2% and a 43.92% success rate. Edwards covers the Consumer Cyclical sector, focusing on stocks such as Next plc, Inditex, and JD Sports Fashion.
PUMA SE NPV has an analyst consensus of Hold, with a price target consensus of $35.02, implying a 37.44% upside from current levels. In a report released yesterday, Deutsche Bank also maintained a Buy rating on the stock with a €34.00 price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Middle East War Reset Dollar's Inverse Link to Stocks, Goldman Says
This month's geopolitical tension focused on the Middle East is re-establishing the dollar's traditional inverse relationship with risk assets, according to Goldman Sachs Group Inc. The last eight trading sessions saw the greenback move in the opposite direction of the S&P 500 Index, in contrast to the positive link to risky assets seen amid the broader selling of US holdings after President Donald Trump launched his trade war earlier this year, Goldman strategists including Stuart Jenkins, Teresa Alves and Isabella Rosenberg wrote in a note Wednesday.
Yahoo
an hour ago
- Yahoo
Wainwright sets over $100 target for Nektar on ‘paradigm-shifting' data
H.C. Wainwright analyst Arthur He raised the firm's price target on Nektar (NKTR) to $120 from $6.50 and keeps a Buy rating on the shares. The company this morning announced positive results from the induction period of its ongoing Phase 2b REZOLVE-AD study evaluating rezpegaldesleukin in patients with moderate to-severe atopic dermatitis, the analyst tells investors in a research note. Citing the drug's 'highly differentiated mechanism of action' compared to currently approved therapies, H.C. Wainwright believes rezpeg 'has the potential to reshape the treatment landscape' for atopic dermatitis. The firm expects to see further improvement in efficacy in the next clinical data update when the 36-week maintenance data is expected to be reported in Q1 of 2026. Nektar says a 'paradigm-shifting' atopic dermatitis drug 'has arrived.' The stock in midday trading is up 134%, or $12.82, to $22.36. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on NKTR: Disclaimer & DisclosureReport an Issue Nektar price target raised to $120 from $6.50 at H.C. Wainwright Why Is Nektar Therapeutics Stock (NKTR) Up 110% Today? Nektar jumps 130% to $21.90 after atopic dermatitis study success Nektar Therapeutics Announces Positive Phase 2b Trial Results Nektar's rezpegaldesleukin meets endpoints in Phase 2b atopic dermatitis trial Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
No Ad Comm ‘not necessarily positive' for Capricor, says Roth Capital
Roth Capital analyst Boobalan Pachaiyappan tells investors in a research note that the FDA's intention not to require an Ad Comm 'at this time' for deramiocel for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy 'may not necessarily be positive news,' and that it believes a promissory Ad Comm meeting would be positive, as a potential positive Ad Comm panel vote would put pressure on the new leadership to approve deramiocel in its current form. The firm reiterates a Buy rating and $31 price target on Capricor shares. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on CAPR: Disclaimer & DisclosureReport an Issue Capricor's deramiocel moves ahead without AdCom, says H.C. Wainwright HHS spokesperson tells Reuters FDA 'actively re-evaluating' Capricor AdCom Capricor Therapeutics provides regulatory update on Deramiocel BLA Roth says 'excessive' Capricor selloff due to 'investor overreaction' Capricor selloff brings buying opportunity, says H.C. Wainwright Sign in to access your portfolio
